Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|May 2, 2015
- Pharmaceutical Technology-05-02-2015
- Volume 39
- Issue 5
UV Laser Marking System Ensures Permanent Marking
Videojet’s 7810 Ultraviolet 2-Watt laser is designed for permanent, high-resolution marking on high-density polyethylene, low-density polyethylene, and synthetic fiber materials.
Videojet’s 7810 Ultraviolet 2-Watt laser is designed for permanent, high-resolution marking on high-density polyethylene, low-density polyethylene, and synthetic fiber materials. The code is resistant to abrasives, chemicals, and sterilization processes.
The laser is capable of marking products at up to 250 per minute and features Videojet’s 360° Arc Software for products on curved lines of movement to ensure consistent coding. The movement compensation software counterbalances the orientation of the products on curved lines of movement ensuring 2D and alphanumeric codes are kept consistently clear for serialization.
Videojet Technologies
Articles in this issue
over 11 years ago
Transdermal Drug Delivery Gains Tractionover 11 years ago
Biomanufacturing Outsourcing Globalization Continuesover 11 years ago
How to Stay Abreast of Shifting Regulations and Remain Compliantover 11 years ago
Considering Continuous Crystallizationover 11 years ago
Fixing Tableting Problemsover 11 years ago
Ensuring the Quality of Biologicalsover 11 years ago
Planning for the Future of Serializationover 11 years ago
Streamlining Raw Materials Testingover 11 years ago
Industry Expert Q&A with Matt Hicksover 11 years ago
Ross Disperser Increases VersatilityRelated to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5